Holen Sie sich die Stockscreener-App
3.42
8.23%
0.26
Handel nachbörslich:
3.44
0.02
+0.58%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAMP?
Forum
Prognose
Aktiensplit
Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten
CAMP4 receives Australian clearance for SYNGAP1 therapy trial By Investing.com - Investing.com South Africa
CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada
Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News
CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia
Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union
CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan
SYNGAP1 Disorder Has No Approved Treatments; CAMP4 Clears Trial - Stock Titan
CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CAMP4 Therapeutics Corp (CAMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CAMP|CAMP4 Therapeutics Corp|Price:3.440|Chg%:+0.280 - TradingKey
CAMP|CAMP4 Therapeutics Corp|Price:3.160|Chg%:+0.150 - TradingKey
TradingKey - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation - Moomoo
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth - Sahm
New strong sell stocks for July 16th - MSN
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 New Hire Gets Option on 8,000 Shares at $4.21 - Stock Titan
New Strong Sell Stocks for July 16th - The Globe and Mail
CAMP News | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
CAMP Q1 2026 Earnings: EPS Surprise Misses Estimates as Company Navigates Early-Stage Pipeline - dars.gov.et
CAMP Q1 2026 Earnings: Wider-Than-Expected Loss Despite 2% Stock UptickEarnings Seasonality - dars.gov.et
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones? - Yahoo Finance
X4 Pharmaceuticals appoints Kelly Gold to board of directors - Investing.com UK
X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com - Investing.com India
Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee - Stock Titan
Camp4 Therapeutics Corporation(NasdaqGM: CAMP) added to Russell 2000 Index - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) added to Russell 2000 Growth Benchmark - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Enterprise value to EBITDA forward of CAMP4 Therapeutics Corporation – BOATS:CAMP - TradingView
Camp4 Therapeutics Corporation(NasdaqGM: CAMP) added to Russell 3000 Index - marketscreener.com
Enterprise value to EBIT forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Enterprise value to revenue forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Price to sales forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
CAMP Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Price to sales forward of CAMP4 Therapeutics Corporation – BOATS:CAMP - TradingView
Camp4 Therapeutics Corp advances industry and policy dialogue on orphan drug accessibility - Traders Union
CAMP4 Therapeutics Corp (CAMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CAMP4 Therapeutics Corporation Actuals & Estimates (NASDAQ:CAMP) - TradingView
CAMP Forecast — Price Target — Prediction for 2027 - TradingView
CAMP4 Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - dars.gov.et
Price to book forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan - The Globe and Mail
CAMP4 Therapeutics Corp (CAMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Camp4 Therapeutics Corp advances regRNA therapy for SYNGAP1-related disorder after Nasdaq feature - Traders Union
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMPCAMP4 Therapeutics Corp Revenue Breakdown - Finviz
CAMP4 lures 3 new hires with 39,000 stock options - Stock Titan
CAMP4 Therapeutics Corp (CAMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CAMP4 Therapeutics Corp (CAMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CAMP4 Therapeutics Corp (CAMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CAMP4 Therapeutics Corp (CAMP) Institutional Confidence - TradingKey
CAMP4 Therapeutics Corp (CAMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CAMP Q1 2026 Earnings: Wider‑Than‑Expected Loss but Stock Gains on Pipeline ProgressLong-Term Guidance - dars.gov.et
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential - Investing.com
JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential By Investing.com - Investing.com Nigeria
CAMP Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue ChallengesEarnings Outlook Update - dars.gov.et
CAMP Q1 2026 Earnings: EPS Misses Estimates, Shares DeclineProfit Cycle Analysis - dars.gov.et
CAMP4 Shareholders Approve Equity Plan Changes and Inducement Plan - The Globe and Mail
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):